Wei Ying Jen, BM BCh, FRCPath
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | Royal College of Pathologists, GB, Fellowship of the Royal College of Pathologists |
| 2015 | National University of Singapore, Singapore, SG, Internal Medicine, Master of Medicine |
| 2015 | University of Oxford, Oxford, Oxfordshire, GB, Master of Arts |
| 2015 | Royal College of Physicians, GB, Membership of the Royal College of Physicians |
| 2012 | University of Oxford, Oxford, Oxfordshire, GB, Bachelor of Medicine and Bachelor of Surgery |
| 2009 | University of Oxford, Oxford, Oxfordshire, GB, Medical Sciences, Bachelor of Arts |
Postgraduate Training
| 2023-2024 | Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Senior Resident, Haematology, National University Cancer Institute, Singapore, Singapore, Singapore |
| 2013-2016 | Resident, Internal Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, General Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, KK Women's & Children's Hospital, Singapore, Singapore |
| 2012-2013 | House Officer, Singapore General Hospital, Singapore, Singapore |
Experience & Service
Faculty Academic Appointments
Adjunct Assistant Professor, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2023 - 2024
Senior Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2019 - 2023
Clinical Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2017 - 2019
Administrative Appointments/Responsibilities
Undergraduate Division Director, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2022 - 2024
System Block Lead, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2021 - 2023
Institutional Committee Activities
Key Opinion Leader, Singapore Translational Cancer Consortium, 2022 - Present
Member, Asia-Pacific Leukaemia Consortium, 2022 - Present
Member, Telemedicine Committee, 2020 - 2024
Member, NUHS App Workgroup, 2020 - 2024
Member, NCIS Right Siting Workgroup, 2019 - 2024
Member, Resident's Research Committee, 2018 - 2019
Member, NCIS Annual Research Meeting Scientific Committee, 2018 - 2020
Chairperson, Institutional Review Board, 2017 - 2019
Member, Residents' Welfare Committee, 2015 - 2016
Honors & Awards
| 2024 | EHA Educational Travel Grant, European Hematology Association |
| 2024 | Conquer Cancer – Eisai Inc. Endowed Merit Award, American Society of Clinical Oncology |
| 2023 | NCIS SHINE Incredible Care Award, Nominated by peers, allied health and supervisors to recognise staff who have contributed significantly to the institution and positively influenced their teams |
| 2022 | The Public Administration Medal (Bronze) (COVID-19), Prime Minister's Office, Singapore |
| 2022 | NCIS SHINE Incredible People Award, National University Cancer Institute, Singapore |
| 2020 | Quality Improvement Project Merit Award, National University Hospital |
| 2020 | Best Trainee Award, Chapter of Haematologists, College of Physicians, Academy of Medicine, Singapore |
| 2017 | Best Senior Resident Tutor Award, University Medicine Cluster, National University Hospital |
| 2016 | Junior Doctor Teaching Award, National University of Singapore Yong Loo Lin School of Medicine |
| 2014 | Best Poster Award, World Congress of Internal Medicine |
| 2012 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2011 | Wellcome Trust Student Elective Prize, Wellcome Trust |
| 2010 | Glaxo Scholarship, St Catherine's College, University of Oxford |
| 2010 | Light Senior Scholarship, St Catherine's College, University of Oxford |
| 2009 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2009 | Gibbs Prize, Pre-Clinical Faculty Office, University of Oxford |
| 2008 | College Exhibition, St Catherine's College, University of Oxford |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
- Bazinet A, Bataller A, Montalban-Bravo G, Chien K, Sasaki K, Jen WY, Swaminathan M, Kadia T, DiNardo C, Ravandi F, Garcia-Manero G, Kantarjian H. PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes. Haematologica, 2025. e-Pub 2025. PMID: 40605709.
- Azevedo RS, Jen WY, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM. Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemia. Haematologica, 2025. e-Pub 2025. PMID: 40568715.
- DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol:JCO2500640, 2025. e-Pub 2025. PMID: 40513054.
- Jen WY, Short NJ. Response to "It might not be whether you get knocked down, but whether you...". Blood Adv, 2025. e-Pub 2025. PMID: 40367413.
- DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Brunmeir, R, Ying, L, Yan, J, Hee, YT, Lin, B, Kaur, H, Leong, QZ, Teo, WW, Choong, G, Jen, WY, Koh, LP, Tan, LK, Chan, E, Ooi, M, Yang, HH, Chng, WJ. EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML. Leukemia 39(3):650-662, 2025. e-Pub 2025. PMID: 39774797.
- Jen, WY, Sasaki, K, Ravandi-Kashani, F, Kadia, TM, Wang, S, Wang, W, Loghavi, S, Daver, N, DiNardo, C, Issa, GC, Abbas, HA, Nasnas, C, Bataller Torralba, A, Urrutia, S, Karrar, OS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Advances 9(4):783-792, 2025. e-Pub 2025. PMID: 39631072.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Sahib, NM, Mohamed, JS, Rashid, MA, Jayalakshmi, Lin, YC, Chee, YL, Fan, BE, De Mel, S, Ooi, M, Jen, WY, Chow, EH. A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML. Cancer medicine 13(22), 2024. e-Pub 2024. PMID: 39560206.
- Alagha, R, Chan, WL, Edwin, TS, Lee, J, Jen, WY, Lip, CK, Smitasin, N, Somani, J. The Mote in Thy Brother's Eyes - Fusarium Solani in Leukemia Host. Infectious Diseases in Clinical Practice 31(2), 2023. e-Pub 2023.
Letters to the Editor
- Nagarajan, C, Jen, WY, Ooi, M, De Mel, S, Soekojo, C, Yoon, SS, Tan, MY, Chen, Y, Li, X, Pokharkar, Y, Tham, SN, Hashim, NB, Awasthi, N, Burkill, SM, Durie, BG, Chng, WJ. A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM). Blood cancer journal 15, 2025.
- Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
Patient Reviews
CV information above last modified July 21, 2025